Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa
Abstract
INTRODUCTION: Pseudomonas aeruginosa is a common cause of serious infections in hospitalized patients and is associated with high rates of hospital morbidity and mortality.
OBJECTIVE: The aim of this study was to identify the risk factors of nosocomial infections caused by piperacillin-tazobactam-resistant P.aeruginosa (PT-RPA).
METHODS: A case-control study was conducted in the Clinical Centre Kragujevac from January 2010 to December 2011.
RESULTS: In the observed period, 79 (38.16%) patients had PT-RPA infections, while 128 (61.84%) patients had infections caused by piperacillin-tazobactam-sensitive P. aeruginosa (PT-SPA). Pneumonia was more frequently found in the PT-RPA group (55.70%) (p < 0.05), whereas urinary tract infections were more frequent in the group of patients with PT-SPA infections (26.56%) (p < 0.01). Multivariate analysis was used to identify an injury on admission (OR = 3.089; 95% CI = 1.438-6.635; p = 0.004), administration of imipenem (OR = 15.027; 95% CI = 1.778-127.021; p = 0.013), meropenem (OR = 2.618; 95% CI = 1.030-6.653; p = 0.043), ciprofloxacin (OR = 3.380; 95% CI = 1.412-8.090; p = 0.006), vancomycin (OR = 4.294; 95% CI = 1.477-12.479; p = 0.007), piperacillin-tazobactam (OR = 4.047; 95% CI = 1.395-11.742; p = 0.010) as independent risk factors associated with PT-RPA infection.
CONCLUSION: In hospitalized patients, the risk of PT-RPA infections is associated with previous administration of imipenem, meropenem, ciprofloxacin, vancomycin,…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.